Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons.

Hummel S, Schmidt D, Kremeyer B, Herrmann B, Oppermann M.

Genes Immun. 2005 Jun;6(4):371-4.

PMID:
15815693
2.

The Black Death and AIDS: CCR5-Delta32 in genetics and history.

Cohn SK Jr, Weaver LT.

QJM. 2006 Aug;99(8):497-503. Review.

PMID:
16880184
3.

HIV and the CCR5-Delta32 resistance allele.

de Silva E, Stumpf MP.

FEMS Microbiol Lett. 2004 Dec 1;241(1):1-12. Review.

4.

HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.

Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):307-13. Review.

PMID:
11873082
5.

The evolutionary history of the CCR5-Delta32 HIV-resistance mutation.

Galvani AP, Novembre J.

Microbes Infect. 2005 Feb;7(2):302-9. Epub 2005 Jan 8. Review.

PMID:
15715976
6.

Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands.

Arenzana-Seisdedos F, Parmentier M.

Semin Immunol. 2006 Dec;18(6):387-403. Epub 2006 Sep 15. Review.

PMID:
16978874
7.

Bubonic plague and HIV. The delta 32 connection.

Goldrick BA.

Am J Nurs. 2003 Dec;103(12):26-7. Review. No abstract available.

PMID:
14705628
8.

Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1).

Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA.

Curr Med Chem. 2007;14(12):1325-34. Review.

PMID:
17504215
9.

CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.

Allers K, Schneider T.

Curr Opin Virol. 2015 Oct;14:24-9. doi: 10.1016/j.coviro.2015.06.007. Epub 2015 Jul 1. Review.

PMID:
26143158
10.

The CCR5-delta32 polymorphism as a model to study host adaptation against infectious diseases and to develop new treatment strategies.

Hütter G, Ganepola S.

Exp Biol Med (Maywood). 2011 Aug;236(8):938-43. doi: 10.1258/ebm.2011.010241. Epub 2011 Jun 29. Review.

PMID:
21715437
11.

Role of CCR5 Delta32 bp deletion in RA and SLE.

Martens HA, Kallenberg CG, Bijl M.

Autoimmunity. 2009 May;42(4):260-2. Review.

PMID:
19811270
12.

[Are prehistoric epidemics reflected in the genetic variability of Danes and in current pathogenesis of HIV infections?].

Eugen-Olsen J, Møller-Jensen A, Nielsen JO.

Ugeskr Laeger. 1998 Dec 21;160(52):7585-8. Review. Danish. No abstract available.

PMID:
9889676
13.

Genomic approaches to the study of HIV‐1 acquisition.

Telenti A, McLaren P.

J Infect Dis. 2010 Nov 1;202 Suppl 3:S382-6. doi: 10.1086/655969. Review.

PMID:
20887229
14.

Human population structure and the adaptive response to pathogen-induced selection pressures.

Novembre J, Han E.

Philos Trans R Soc Lond B Biol Sci. 2012 Mar 19;367(1590):878-86. doi: 10.1098/rstb.2011.0305. Review.

15.

Potential roles for chemokine receptor CCR5 in the pathobiology of hepatitis C infection.

Laurence J.

Gastroenterology. 2002 Jun;122(7):2069-72. Review. No abstract available.

PMID:
12055611
16.

C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.

Barmania F, Pepper MS.

Appl Transl Genom. 2013 May 26;2:3-16. eCollection 2013 Dec 1. Review.

17.

Genome editing-based HIV therapies.

Gu WG.

Trends Biotechnol. 2015 Mar;33(3):172-9. doi: 10.1016/j.tibtech.2014.12.006. Epub 2015 Jan 15. Review.

PMID:
25600622

Supplemental Content

Support Center